Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum

Name	Symbol	Market	Type
Capital Group Fixed Income ETF Trust	AMEX:CGCP	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

Capital Group Fixed Income ETF Trust

AMEX:CGCP

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	22.48				0	09:09:54

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.00

0.00%

22.48

09:09:54

Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum

06/01/2010 12:30pm

PR Newswire (US)

Capital Group Fixed Inco... (AMEX:CGCP)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Capital Group Fixed Inco... Charts.

IRVINE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) today announced that it is scheduled to present at the 2010 OneMedPlace Finance Forum to be held at the Sir Francis Drake Hotel in San Francisco. Executive Chairman, Paul J. McCormick will present a 30-minute corporate overview next Tuesday, January 12, 2010 at 3:00 pm Pacific time (6:00 pm Eastern time) and meet one-on-one with investors during the conference. The annual OneMedForum provides an opportunity for the most promising emerging healthcare and life science companies to present to and interact with a diverse group of global investors and partners. The forum is held at the Sir Francis Drake Hotel in San Francisco, during the Healthcare community's largest gathering of the year - the JP Morgan Healthcare Conference. Throughout the two days, over 100 CEOs will present their company to 500+ OneMedForum guests. In attendance will be institutional investors, venture capitalists, private investors, business development executives, and industry executives from across the healthcare landscape. About Cardiogenesis Corporation Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com/ or the direct to patient website at http://www.heartofnewlife.com/. DATASOURCE: Cardiogenesis Corporation CONTACT: Paul McCormick, Executive Chairman of Cardiogenesis Corporation, +1-949-420-1808 Web Site: http://www.cardiogenesis.com/ http://www.heartofnewlife.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CGCP Capital Group Fixed Income ETF Trust